Kingsview Wealth Management LLC Has $1.91 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Kingsview Wealth Management LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,797 shares of the medical research company’s stock after selling 144 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,910,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of EW. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $30,000. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC raised its holdings in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $46,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,000 shares of company stock worth $547,430 over the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $71.05 on Tuesday. The company has a market capitalization of $41.91 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 3.64 and a beta of 1.10. The company has a 50-day moving average of $72.45 and a 200-day moving average of $69.18. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Analysts Set New Price Targets

A number of research analysts have recently commented on EW shares. Piper Sandler lowered their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Truist Financial reissued a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.